Phibro Animal Health Corporation (PAHC) Q1 2027 earnings review
Phibro's mineral sales rise fast, but Animal Health profit falls
Phibro Animal Health, a maker of livestock medicines and feed minerals, grew through its smaller divisions while profit in its main medicine unit slipped. Total revenue rose 6%, beating management's expectations because trace minerals and specialty chemicals jumped. Chief executive Dani Bendheim kept the full-year outlook unchanged, which by our math leaves revenue growth slowing to 3% for the rest of the year.
| Revenue | $386.8M +6% from a year ago |
|---|---|
| Adjusted EBITDA | $64.3M +4% from a year ago |
| Profit per share, excluding one-offs | $0.79 +8% from a year ago |
| Full-year outlook | Unchanged middle of the range: 4% sales growth |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because temporary timing gains balanced out core cost pressures. Operating profit before depreciation beat the prior quarter's call for a decline, and twelve-month free cash flow more than doubled to $22 million. One caution: core Animal Health profit still fell 1% on higher staff pay even though some costs shifted into next quarter, and Brazil's antibiotic ban cut sales by $5 million.
The question now is whether the full-year outlook is cautious or relies on one-offs and tax cuts to hit its profit target. Optimists point to underlying feed medicine demand and potential Brazilian regulatory approval as upside, while sceptics note that delayed first-quarter costs and shrinking vaccine sales will squeeze margins next quarter. Second-quarter Animal Health profit and a Brazilian regulatory decision will settle it.
🐂 Bull Case
Smaller Divisions Drove the First-Quarter Sales Beat
Phibro makes medicines and vaccines for farm animals, alongside trace minerals for livestock feed and specialty chemicals. Chief executive Dani Bendheim said that "the outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products". Those two smaller divisions supplied more than half of the company's total revenue growth this quarter.
- Mineral Nutrition sales: $73.6 million, up 17% from a year ago
- Performance Products sales: $20.2 million, up 16% from a year ago
- Mineral Nutrition operating profit before depreciation (Adjusted EBITDA): $6.2 million, up 36%
- Performance Products Adjusted EBITDA: $2.8 million, up 75%
Mineral Nutrition grew because of "an increase in demand and average selling prices for zinc oxide, copper and trace minerals", the company said. Performance Products rebounded from an 8% drop last fiscal year on copper-based and fluoride demand, while its gross profit also got a boost from "the impact of IEEPA tariff recoveries in the quarter". What to watch: whether Performance Products keeps growing in the second quarter without one-time tariff refunds.
Factory Savings Held Underlying Gross Margin Steady
The livestock medicine maker recently finished a three-year efficiency programme called Phibro Forward and is consolidating factories bought from Zoetis in October 2024. Reported gross margin rose 0.3 percentage points to 33.2% of sales because cost of goods sold—the direct cost of making its products—dropped from 67.1% of sales to 66.8% as last year's $1.1 million purchase-accounting charge did not repeat.
Excluding one-offs, gross margin held at 34.0% as higher prices and volumes offset rising input and shipping costs, plus the loss of $5.2 million in high-margin Brazilian antibiotic sales. Phibro also booked $0.6 million in severance for the "planned closure of the Chicago Heights manufacturing facility" next summer. What to watch: gross margin excluding one-offs in the second quarter, when a steady 34% reading will show efficiency gains are covering lost Brazilian sales.
Cash Generation Rose as Inventory Focus Began
Free cash flow—cash from operations minus factory spending—dropped to $9.9 million in fiscal 2026 because the animal health group built up inventory after its Zoetis deal. "We generated positive cash flow in the first quarter, and we see a clear opportunity to do more, particularly in managing inventory," Bendheim said. Over the twelve months ended September, free cash flow more than doubled from June's twelve-month level to $21.7 million.
That improvement eased immediate pressure on the balance sheet, allowing the New Jersey company to add $1.1 million in cash while keeping leverage steady. Still, twelve-month free cash flow remains down 37% from the $34.3 million recorded a year ago. What to watch: the exact first-quarter inventory build in the upcoming quarterly filing, because full-year cash generation rests on keeping inventory growth under $30 million.
Positives this quarter didn't test
One standing growth investment received no new data in the earnings release because the company did not include a full cash flow statement.
- Vaccine factory expansion in Ireland and Israel: capital spending for the quarter was not disclosed; the quarterly filing's cash flow statement will show whether spending stepped up as planned.
🐻 Bear Case
Higher Staff Costs Lowered Animal Health Profit
Animal Health is Phibro's core division, bringing in three-quarters of total revenue. Bendheim said the division delivered operating profit before depreciation, or Adjusted EBITDA, ahead of internal targets, "including the benefit of certain costs that shifted into the second quarter". Even with those delayed expenses helping the quarter, Animal Health Adjusted EBITDA fell 1% from a year ago to $73.9 million, pushing its margin down 1.2 percentage points to 25.2%.
Profit fell because selling, general and administrative expenses—staff pay and overhead—rose faster than sales. Across the whole company, reported overhead climbed from 18.8% of revenue to 20.4%, as last year benefited from $3.8 million in insurance proceeds. Excluding one-offs, overhead still rose 0.4 percentage points to 20.0% of revenue on $5.9 million of higher Animal Health employee costs, pulling company-wide operating margin down 1.3 percentage points to 12.8%.
What to watch: Animal Health Adjusted EBITDA margin in the second quarter. When the delayed first-quarter expenses arrive alongside higher staff pay, a further drop below 25% would show that overhead is eating into core profit.
Brazil Rules Cut Medicated Feed Sales
Over half of Phibro's revenue comes from medicated feed additives (MFAs), which are antibiotics and other treatments mixed into livestock feed. Brazil banned the use of its antibiotic virginiamycin for promoting animal growth earlier this year, and the company is waiting for regulators to approve therapeutic-use claims instead. "With the election now behind us, we are optimistic that progress on those approvals may be forthcoming," Bendheim said.
- Brazil virginiamycin sales: down $5.2 million from a year ago
- Total MFA and other sales: $206.5 million, up 6% (or up 8.5% excluding the Brazil drop, by our math)
- Nutritional specialty sales: $47.1 million, down 2% on weaker North American poultry and South American fish-farming demand
- Vaccine sales: $39.5 million, down 2% on lower Brazilian poultry demand and timing in Asia
The company stopped breaking out the MFA portfolio it bought from Zoetis after its sales fell 11% last quarter, so investors cannot see how that acquired line performed within the 6% MFA gain. Meanwhile, the full-year outlook continues to "assume no additional virginiamycin sales in Brazil for the remainder of the fiscal year". What to watch: Brazilian regulatory approval before the second-quarter release, because another delay leaves Animal Health leaning on mature products while vaccines and nutritional specialties shrink.
Risks this quarter didn't answer
Two standing operational risks got no new numbers in the press release.
- Israel plant and currency exposure: the shekel drove a $0.4 million currency gain, but plant-level operations and asset exposure await the quarterly filing.
- Chicago Heights non-cash write-offs: the company recorded $0.6 million in severance, but total non-cash asset write-downs for the factory closure remain unestimated.
💲 Other KPIs
Total debt ticked up by $1.7 million from June to $739.6 million, while cash rose $1.1 million to $83.1 million. Gross leverage—total debt divided by the last twelve months of Adjusted EBITDA—held steady at 2.9 times, down from 3.3 times a year ago as twelve-month profit grew.
The tax rate excluding one-offs fell 1.4 percentage points from 25.9% a year ago, which Phibro said was "primarily due to the mix of income". Even so, the first-quarter rate sits 4.5 percentage points above the company's full-year target of about 20%, and resolving a foreign tax audit later this year could lower it.
Net interest costs dropped 6%, or $0.8 million, from $12.1 million a year ago. Lower interest rates and interest received on tariff refunds more than offset higher average daily borrowings on the revolving credit line during the quarter.
🔮 Guidance
Unchanged. The plan calls for about 4% revenue growth at the middle of the range. After 6.3% growth in the first quarter, that leaves about 3.0% growth for the rest of the year by our math, as the loss of Brazilian virginiamycin sales weighs on the remaining three quarters.
Unchanged. Management still expects operating profit before depreciation and one-offs to rise about 3% at the middle of the range. By our math, the middle of the range leaves 2.9% growth for the rest of the year, down from 3.9% in the first quarter because delayed expenses shift into the second quarter and last year's fourth quarter included an $8.5 million tariff refund.
Unchanged. The forecast has reported profit growing 27% at the middle of the range. By our math, that implies 33.2% growth for the rest of the year vs 11.3% in the first quarter, because the plan assumes zero currency losses after absorbing $12.6 million of currency losses in fiscal 2026.
Unchanged. Reported profit per share is set to grow 27% at the middle of the range, up from 10.8% growth in the first quarter, tracking the reported net income outlook on a steady count of 41 million shares.
Unchanged. Profit excluding one-offs is planned to rise 9% at the middle of the range. By our math, that requires 9.0% growth over the rest of the year, matching the first quarter's 9% increase as a lower planned tax rate offsets slower operating profit growth.
Unchanged. Profit per share excluding one-offs is planned to grow 9% at the middle of the range. After growing 8.2% to $0.79 in the first quarter, the middle of the range leaves 8.8% growth for the rest of the year by our math.
Unchanged. The livestock group kept its full-year tax rate target at about 20%, down from 23.7% in fiscal 2026. Hitting 20% for the year requires the rate to step down over the next three quarters from the first quarter's 24.5% reading.
❓ Key Questions
How much did the Zoetis portfolio grow this quarter?
Phibro stopped reporting the acquired Zoetis medicated feed portfolio separately right after its sales fell 11% in the fourth quarter. Without that figure, investors cannot tell if the acquired products grew inside the 6% category gain.
How large were the tariff refunds in Q1?
Management said tariff refunds lifted both Performance Products gross profit and net interest income, but did not give the dollar amounts. Knowing the size shows how much of the first-quarter profit beat was one-time.
How much cost shifted from Q1 into Q2?
Chief executive Dani Bendheim said Animal Health profit beat internal plans partly because certain expenses moved into the second quarter. Quantifying that shift will show the underlying profit trend in the core division.
Why is the full-year tax target still 20%?
The tax rate excluding one-offs was 24.5% in the first quarter, well above the 20% full-year target. Management noted a possible foreign tax audit resolution but said its impact cannot yet be estimated.